BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 31232159)

  • 21. DBC1 is a key positive regulator of enhancer epigenomic writers KMT2D and p300.
    Kim HJ; Moon SJ; Hong S; Won HH; Kim JH
    Nucleic Acids Res; 2022 Aug; 50(14):7873-7888. PubMed ID: 35801925
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mitochondrial DNA damage is sensitive to exogenous H(2)O(2) but independent of cellular ROS production in prostate cancer cells.
    Chan SW; Nguyen PN; Ayele D; Chevalier S; Aprikian A; Chen JZ
    Mutat Res; 2011 Nov; 716(1-2):40-50. PubMed ID: 21843533
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis.
    Zhang J; Dominguez-Sola D; Hussein S; Lee JE; Holmes AB; Bansal M; Vlasevska S; Mo T; Tang H; Basso K; Ge K; Dalla-Favera R; Pasqualucci L
    Nat Med; 2015 Oct; 21(10):1190-8. PubMed ID: 26366712
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PAGE4 promotes prostate cancer cells survive under oxidative stress through modulating MAPK/JNK/ERK pathway.
    Lv C; Fu S; Dong Q; Yu Z; Zhang G; Kong C; Fu C; Zeng Y
    J Exp Clin Cancer Res; 2019 Jan; 38(1):24. PubMed ID: 30658679
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The SRA protein UHRF1 promotes epigenetic crosstalks and is involved in prostate cancer progression.
    Babbio F; Pistore C; Curti L; Castiglioni I; Kunderfranco P; Brino L; Oudet P; Seiler R; Thalman GN; Roggero E; Sarti M; Pinton S; Mello-Grand M; Chiorino G; Catapano CV; Carbone GM; Bonapace IM
    Oncogene; 2012 Nov; 31(46):4878-87. PubMed ID: 22330138
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Histone methyltransferase KMT2D mediated lipid metabolism via peroxisome proliferator-activated receptor gamma in prostate cancer.
    Zhai Q; Luo M; Zhang Y; Zhang W; Wu C; Lv S; Wei Q
    Transl Cancer Res; 2022 Aug; 11(8):2607-2621. PubMed ID: 36093518
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comprehensive pharmacogenomic profiling of human papillomavirus-positive and -negative squamous cell carcinoma identifies sensitivity to aurora kinase inhibition in KMT2D mutants.
    Kalu NN; Mazumdar T; Peng S; Tong P; Shen L; Wang J; Banerjee U; Myers JN; Pickering CR; Brunell D; Stephan CC; Johnson FM
    Cancer Lett; 2018 Sep; 431():64-72. PubMed ID: 29807113
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MDC1 functionally identified as an androgen receptor co-activator participates in suppression of prostate cancer.
    Wang C; Sun H; Zou R; Zhou T; Wang S; Sun S; Tong C; Luo H; Li Y; Li Z; Wang E; Chen Y; Cao L; Li F; Zhao Y
    Nucleic Acids Res; 2015 May; 43(10):4893-908. PubMed ID: 25934801
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association analysis of KMT2D copy number variation as a positional candidate for growth traits.
    Cheng J; Jiang R; Yang Y; Cao X; Huang Y; Lan X; Lei C; Hu L; Chen H
    Gene; 2020 Aug; 753():144799. PubMed ID: 32446916
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel synthetic protoapigenone analogue, WYC02-9, induces DNA damage and apoptosis in DU145 prostate cancer cells through generation of reactive oxygen species.
    Chen HM; Chang FR; Hsieh YC; Cheng YJ; Hsieh KC; Tsai LM; Lin AS; Wu YC; Yuan SS
    Free Radic Biol Med; 2011 May; 50(9):1151-62. PubMed ID: 21256211
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epigenetic disruption of miR-130a promotes prostate cancer by targeting SEC23B and DEPDC1.
    Ramalho-Carvalho J; Martins JB; Cekaite L; Sveen A; Torres-Ferreira J; Graça I; Costa-Pinheiro P; Eilertsen IA; Antunes L; Oliveira J; Lothe RA; Henrique R; Jerónimo C
    Cancer Lett; 2017 Jan; 385():150-159. PubMed ID: 27984115
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of FOXO3 in DNA damage response in thyrocytes.
    Klagge A; Weidinger C; Krause K; Jessnitzer B; Gutknecht M; Fuhrer D
    Endocr Relat Cancer; 2011 Oct; 18(5):555-64. PubMed ID: 21712344
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The phytochemical 3,3'-diindolylmethane decreases expression of AR-controlled DNA damage repair genes through repressive chromatin modifications and is associated with DNA damage in prostate cancer cells.
    Palomera-Sanchez Z; Watson GW; Wong CP; Beaver LM; Williams DE; Dashwood RH; Ho E
    J Nutr Biochem; 2017 Sep; 47():113-119. PubMed ID: 28582660
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aryl Hydrocarbon Receptor Suppresses the Prostate Cancer LNCaP Cell Growth and Invasion by Promoting DNA Damage Response Under Oxidative Stress.
    Yu JS; Leng PF; Li YF; Wang YQ; Wang Y; An RH; Qi JP
    DNA Cell Biol; 2017 Nov; 36(11):1010-1017. PubMed ID: 28972393
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Histone H3 lysine 4 methyltransferase KMT2D.
    Froimchuk E; Jang Y; Ge K
    Gene; 2017 Sep; 627():337-342. PubMed ID: 28669924
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oxidative stress induces ADAM9 protein expression in human prostate cancer cells.
    Sung SY; Kubo H; Shigemura K; Arnold RS; Logani S; Wang R; Konaka H; Nakagawa M; Mousses S; Amin M; Anderson C; Johnstone P; Petros JA; Marshall FF; Zhau HE; Chung LW
    Cancer Res; 2006 Oct; 66(19):9519-26. PubMed ID: 17018608
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In Vivo Genetic Screens of Patient-Derived Tumors Revealed Unexpected Frailty of the Transformed Phenotype.
    Bossi D; Cicalese A; Dellino GI; Luzi L; Riva L; D'Alesio C; Diaferia GR; Carugo A; Cavallaro E; Piccioni R; Barberis M; Mazzarol G; Testori A; Punzi S; Pallavicini I; Tosti G; Giacó L; Melloni G; Heffernan TP; Natoli G; Draetta GF; Minucci S; Pelicci P; Lanfrancone L
    Cancer Discov; 2016 Jun; 6(6):650-63. PubMed ID: 27179036
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development.
    Ortega-Molina A; Boss IW; Canela A; Pan H; Jiang Y; Zhao C; Jiang M; Hu D; Agirre X; Niesvizky I; Lee JE; Chen HT; Ennishi D; Scott DW; Mottok A; Hother C; Liu S; Cao XJ; Tam W; Shaknovich R; Garcia BA; Gascoyne RD; Ge K; Shilatifard A; Elemento O; Nussenzweig A; Melnick AM; Wendel HG
    Nat Med; 2015 Oct; 21(10):1199-208. PubMed ID: 26366710
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Integrative molecular characterization of Chinese prostate cancer specimens.
    Lv SD; Wang HY; Yu XP; Zhai QL; Wu YB; Wei Q; Huang WH
    Asian J Androl; 2020; 22(2):162-168. PubMed ID: 31134918
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Histone deacetylase SIRT6 regulates chemosensitivity in liver cancer cells via modulation of FOXO3 activity.
    Hu JQ; Deng F; Hu XP; Zhang W; Zeng XC; Tian XF
    Oncol Rep; 2018 Dec; 40(6):3635-3644. PubMed ID: 30542728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.